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Nitric Oxide–Producing Myeloid-Derived Suppressor
Cells Inhibit Vascular E-Selectin Expression in Human
Squamous Cell Carcinomas
Ahmed E. Gehad1,4, Michael K. Lichtman1,4, Chrysalyne D. Schmults1, Jessica E. Teague1,
Adam W. Calarese2, Ying Jiang3, Rei Watanabe1 and Rachael A. Clark1
Squamous cell carcinomas (SCCs) are sun-induced skin cancers that are particularly numerous and aggressive
in immunosuppressed individuals. SCCs evade immune detection at least in part by downregulating E-selectin
on tumor vessels, thereby restricting entry of skin-homing T cells into tumors. We find that nitric oxide (NO)
potently suppresses E-selectin expression on human endothelial cells and that SCCs are infiltrated by NO-
producing iNOSþ CD11bþ CD33þ CD11c HLA-DR myeloid-derived suppressor cells (MDSCs). MDSCs from
SCCs produced NO, transforming growth factor-b (TGF-b), and arginase, and inhibited endothelial E-selectin
expression in vitro. MDSCs from SCCs expressed the chemokine receptor CCR2 (chemokine (C-C motif)
receptor 2) and tumors expressed the CCR2 ligand human b-defensin 3 (HBD3), suggesting that CCR2/HBD3
interactions may contribute to MDSC recruitment to SCCs. Treatment of SCCs in vitro with the inducible nitric
oxide synthase (iNOS) inhibitor No-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable
to imiquimod-treated SCCs undergoing immunologic destruction. Our results suggest that local production of
NO in SCCs may impair vascular E-selectin expression. We show that MDSCs are critical producers of NO in
SCCs and that NO inhibition restores vascular E-selectin expression, potentially enhancing T-cell recruitment.
The iNOS inhibitors and other therapies that reduce NO production may therefore be effective in the treatment
of SCCs and their premalignant precursor lesions, actinic keratoses.
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INTRODUCTION
Over 700,000 squamous cell carcinomas (SCCs) are diag-
nosed each year in the United States (Rogers et al., 2010). The
treatment of nonmelanoma skin cancers, of which SCC is the
second most frequent type, account for 4.5% of all Medicare
cancer costs (Berg and Otley, 2002; Housman et al., 2003).
Although most are curable by surgical excision, 4%
metastasize to the lymph nodes and 1.5% of SCC patients
die from metastatic or locally aggressive disease (Brantsch
et al., 2008). SCCs are a leading cause of death among organ-
transplant recipients. These patients have a 65- to 250-fold
increased risk of developing SCCs; nearly 10% of these
cancers metastasize and the majority of patients die as a
result (Berg and Otley, 2002; Euvrard et al., 2003). Currently,
wide surgical excision is the only treatment for invasive SCCs.
In addition to the burden of invasive cancers, actinic
keratoses, the premalignant precursor lesion of SCCs, are
the third most frequent reason in the United States for
consulting a dermatologist (Feldman et al., 1998). Over 5.2
million physician visits are made each year for the treatment
of actinic keratoses at a cost of over $900 million (Warino
et al., 2006).
Immune evasion in human SCCs appears to primarily
result from aberrant T-cell homing. Vessels in SCCs lack
expression of E-selectin, a skin addressin that is expressed at
baseline by cutaneous postcapillary venules, is upregulated
with inflammation, and by binding to cutaneous lympho-
cyte antigen (CLA) on skin-homing T cells, mediates the first
step of T-cell recruitment into skin (Chong et al., 2004;
Kupper and Fuhlbrigge, 2004; Clark et al., 2008). As a
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result, these tumors exclude CLAþ skin-homing T cells, the
cell type that provides cutaneous immune surveillance and
would be expected to contain tumor-specific T cells
(Clark, 2010).
Topical treatment of SCCs with the Toll-like receptor 7
(TLR7) agonist imiquimod induces endothelial activation,
massive infiltration of tumors by CLAþ T cells producing IFN-g,
perforin, and granzyme, tumor cell death, and histologic
evidence of tumor regression (Clark et al., 2008; Huang
et al., 2009). This rapid and effective immune response
suggests that primed SCC-specific T cells exist in the
circulation but these cells cannot gain access to the tumor.
Imiquimod can be used to treat SCCs in poor surgical
candidates (Peris et al., 2006). In solid organ-transplant
recipients, a course of imiquimod was effective and did not
engender graft rejection in the 6 or 12 months that patients
were followed (Brown et al., 2005; Ulrich et al., 2007) but
concerns linger that repeated use of imiquimod could
engender graft rejection or shorten the life of an allograft.
There is therefore a need to understand why blood vessels in
SCCs fail to express T-cell homing addressins such as
E-selectin and to identify new agents that can induce
endothelial activation and restore appropriate T-cell homing
without broad, nonspecific activation of the immune
system. Below, we present our findings that nitric oxide
(NO) production in SCCs contributes to suppression of E-
selectin expression by tumor vessels and that agents that
inhibit NO production may be effective therapeutic
strategies for the treatment of SCCs.
RESULTS
Vascular E-selectin expression correlates with tumor infiltration
by CLAþ T cells and histologic evidence of tumor regression
We previously observed qualitative increases in vascular
E-selectin expression and T-cell infiltration after TLR7 agonist
treatment of SCCs (Clark et al., 2008; Huang et al., 2009). To
quantitatively study the relationship of vascular E-selectin
expression and tumor infiltration by skin-homing CLAþ
T cells, we counted the percentage of tumor vessels
expressing E-selectin and the number of infiltrating CLAþ
T cells in untreated SCCs and SCCs treated with TLR7 agonist
before excision. In agreement with earlier observations,
vascular E-selectin expression was absent or low in untreated
tumors and markedly upregulated in SCCs treated with the
TLR7 agonist imiquimod (Figure 1a and d). In untreated
tumors, 6.7% of blood vessels in tumors expressed E-selectin
(n¼5, SEM 1.53), whereas 34.2% of blood vessels expressed
E-selectin in tumors treated with TLR7 agonist before excision
(n¼3, SEM 3.04). The difference between treated and
untreated SCCs was statistically significant (Po0.0001). Simi-
larly, recruitment of CLAþ T cells was low in untreated SCCs
but greatly enhanced in treated tumors (Figure 1b-d). Untreated
tumors were infiltrated by a mean 21.3 CLAþ T cells per high-
power field (HPF, n¼ 6, SEM 5.91), whereas tumors treated
with TLR7 agonist before excision contained a mean 256.6
CLAþ T cells per HPF (n¼3, SEM 47.2, P¼ 0.0002). There
was in fact a strong linear correlation between vascular
E-selectin expression and infiltration by CLAþ T cells (correla-
tion coefficient R¼0.94) and only tumors with both features
had histologic evidence of tumor regression (Figure 1d).
SCCs are infiltrated by NO-producing CD11cCD11bþ
HLA-DR myeloid-derived suppressor cells
Cells expressing inducible nitric oxide synthase (iNOS) were
prominent in untreated SCCs (Figure 2a and b; Clark et al.,
2008). We previously observed faint staining of iNOSþ cells
for CD11c, suggesting a possible dendritic cell lineage.
However, follow-up staining with multiple anti-CD11c
antibodies demonstrated that these cells were in fact
CD11c, CD11bþ , and HLA-DR, a phenotype shared by
myeloid-derived suppressor cells (MDSCs) identified in
several human cancers (Figure 2c, d, and h; Filipazzi et al.,
2007; Diaz-Montero et al., 2009; Corzo et al., 2010; Gabitass
et al., 2011). iNOSþ cells lacked expression of the
macrophage marker CD163, the T-cell marker CD3, and
the endothelial cell marker CD34 (Figure 2e-g) and were
CD14 (data not shown). Further characterization by flow
cytometry analysis of dispersed cells isolated from collage-
nase-treated SCCs demonstrated that CD11bþ HLA-DR
cells expressed CD33, a subset expressed iNOS, and the
majority expressed transforming growth factor-b (TGF-b), a
phenotype consistent with human MDSCs (Figure 3a). Real-time
PCR analysis of CD11bþ cells isolated by magnetic bead
separation from collagenase-dispersed tumors demonstrated that
CD11bþ cells expressed arginase I (Figure 3b). iNOSþ
CD11bþCD11cHLA-DR cells were present in 16/16 un-
treated SCCs (10 SCCs were studied by immunostaining of
cryosections and 6 by flow cytometry analysis of collagenase-
treated tumors). As we previously reported, iNOSþ cells were
not present in imiquimod-treated SCCs undergoing regression
(Clark et al., 2008). CD11bþ HLA-DR cells made up a mean
6% of total tumor cells in collagenase-digested SCCs but were
rare (0.8%) in normal human skin (Figure 3c). Selective gating on
iNOS-expressing cells demonstrated that MDSCs were the
prominent cell type expressing iNOS in most tumors, although
it was also expressed by other cell types within the tumor
microenvironment (Figure 3d). A mean 51% of total iNOSþ
cells in four collagenase-digested SCCs were CD11bþ CD11c
HLA-DR CD33þ MDSCs (SEM 10.3).
To confirm that NO was produced within the SCC tumor
microenvironment, we measured nitrate and nitrite levels
from tumor supernatants using the Griess method (Figure 3e).
Although levels varied, significant NO production was
observed in all tumors analyzed (significance of difference
medium vs. SCC supernatants, Po0.05). To confirm that
MDSCs in SCCs produced NO, we isolated CD11bþ cells
using magnetic bead separation of collagenase-dispersed
tumors. CD11b enrichment produced a fairly uniform
population of CD11bþ HLA-DRlow cells (Figure 3f) and
analysis of the culture supernatants of these cells demon-
strated that they produced NO (Figure 3g).
NO inhibits E-selectin expression by human dermal
microvascular endothelial cells in vitro
NO inhibits the expression of endothelial adhesion receptors
on human umbilical vein endothelial cells (HUVECs) and
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reduces adhesion of dendritic cells to endothelial monolayers
in vitro (De Caterina et al., 1995; De Palma et al., 2006).
Gene expression analyses have found significant differences
between HUVECs and the microvascular endothelial cells
found in tissues such as the skin (Chi et al., 2003). We studied
the effects of NO on human dermal microvascular endothe-
lial cells (DMECs). To mimic the physiologic stimulation
likely to occur within the tumor microenvironment, DMECs
were co-cultured with TLR7 agonist-stimulated T-cell-
depleted peripheral blood mononuclear cells antigen pre-
senting cells (APCs). Under these conditions, NO potently
inhibited endothelial E-selectin expression (Figure 4a and b).
However, NO only partially inhibited E-selectin expression
when endothelial cells were stimulated with 10 ngml1
of tumor necrosis factor-a (TNF-a). A similar biology was
observed in HUVECs; NO completely inhibited E-selectin
expression after physiologic stimulation with APCs but only
partially inhibited expression after intense endothelial stimu-
lation with TNF-a (Figure 4b).
MDSCs from SCCs suppress endothelial E-selectin expression
in vitro
To determine if cell types in SCCs are capable of suppressing
endothelial E-selectin expression, we cultured HUVECs in the
presence of unfractionated cells from collagenase-dispersed
SCC tumors. We observed a modest suppression of E-selectin
under these conditions (Figure 4c). We then separated
collagenase-dispersed SCCs into CD11bþ and CD11b
fractions using magnetic bead separation (Figure 3f) and
tested the ability of these cells to suppress endothelial E-
selectin expression (Figure 4d and e). CD11bþ cell fractions
reproducibly inhibited endothelial E-selectin expression,
whereas CD11b fractions had no effect or modestly
increased E-selectin expression.
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Figure 1. E-selectin expression on tumor vasculature correlates quantitatively with infiltration by CLAþ T cells. (a) Untreated human squamous cell
carcinomas (SCCs) lacked vascular expression of the skin T-cell-homing addressin E-selectin. Cryosections of tumor were costained for CD31 (a blood vessel
marker, left panels) and E-selectin (right panels). SCCs treated with the Toll-like receptor 7 (TLR7) agonist imiquimod showed upregulation of E-selectin
expression on tumor vessels (lower panels). Similar findings have been demonstrated in a total of 12 untreated tumors and six imiquimod-treated tumors. Scale
bar¼ 100 mM. (b) CLAþ T cells are excluded from untreated human SCCs but are present in imiquimod-treated tumors. Shown are T cells isolated from untreated
(upper panel) and imiquimod-treated (lower panel) SCC tumors. (c) Exclusion of CLAþ T cells from SCCs was reversed by topical treatment with TLR7 agonist
before excision. The absolute numbers of CLAþ T cells per high-power field (HPF) infiltrating untreated SCCs (gray bars) and TLR7 agonist-treated tumors (TLR7,
black bars) are shown. (d) Vascular E-selectin expression correlated with the number of cutaneous lymphocyte antigen (CLA)-expressing T cells infiltrating SCCs
and histologic evidence of tumor regression. The mean and SEM for both the number of CLA-expressing T cells and the % E-selectin positive vessels are shown.
These studies demonstrate a strong correlation of vascular E-selectin expression with the ability of tumors to recruit CLAþ skin-homing T cells. Tumors
designated with an asterisk (*) had histologic evidence of tumor regression.
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MDSCs from SCCs express CCR2 and SCCs produce the CCR2
ligand HBD3
MDSCs from both mice and humans express the chemokine
receptor CCR2 (chemokine (C-C motif) receptor 2) and CCL2
(chemokine (C-C motif) ligand 2) production by human
tumors has been implicated in the migration of MDSCs into
tumors (Huang et al., 2007). MDSCs from collagenase-
dispersed SCCs expressed CCR2 by flow cytometry analysis,
whereas T cells from the same tumors did not (Figure 5a).
Coimmunostaining for iNOS and CCR2 in tumor cryosections
confirmed that iNOSþ cells expressed CCR2 (Figure 5b).
Quantitative reverse transcriptase–PCR analysis of SCC
tumors showed that the CCL2 ligands CCL2, CCL7, CCL13,
and human b-defensin 2 (HBD2) were expressed at compar-
able levels in normal skin and SCCs, whereas only the CCL2
ligand HBD3 was expressed at significantly higher levels in
SCCs (Figure 5c). Immunostaining of SCC cryosections
confirmed production of HBD3 in SCC tumors (Figure 5d).
iNOS inhibition induces SCC vascular E-selectin expression
in vitro
To determine if NO production in tumors locally inhibits
vascular E-selectin expression, we cultured portions of
human SCCs for 24 hours in the iNOS inhibitor No-nitro-L-
arginine(L-NNA) in the presence or absence of TNF-a and
then assayed for E-selectin expression by immunostaining
of cryosections. We observed a marked upregulation of
E-selectin expression in tumors treated with the iNOS
inhibitor (Figure 6a and b). E-selectin was expressed on a
mean 1.9% of blood vessels in SCCs treated with control
medium (n¼ 4 tumors, SEM 0.58). After treatment with iNOS
inhibitor, E-selectin was expressed by a mean 27.1% of tumor
vessels (n¼4, SEM 1.06, control medium vs. iNOS inhibitor
Po0.0001). As expected, treatment of SCCs with TNF-a also
increased expression of E-selectin (mean 19.6% positive
vessels, SEM 2.17, n¼4, control medium vs. TNF-a treated
P¼0.0002). Combining iNOS inhibition and treatment with
TNF-a provided no additional increase in E-selectin expres-
sion above the use of iNOS inhibitors alone (iNOS inhibitor
vs. TNF-a/iNOS inhibitor P¼ 0.45).
DISCUSSION
Impairment of T-cell homing is a major mechanism by which
cutaneous SCCs evade immune responses. Vessels in SCC
tumors lack expression of E-selectin and exclude the
population of CLAþ T cells thought to provide immune
surveillance in the skin (Clark et al., 2008). Induction of
E-selectin expression on blood vessels by TLR7 agonist
therapy leads to infiltration of the tumors by CLAþ T cells
producing IFN-g, perforin, and granzyme, and is associated
with histologic evidence of tumor regression (Clark et al.,
2008; Huang et al., 2009). These clinical responses suggest
that tumor-specific T cells exist within the circulation but
cannot gain access to the tumor. Thus, the induction of
appropriate T-cell homing addressins on tumor vessels has
the potential to restore homing and potentially induce tumor
destruction.
We report here that human SCCs are infiltrated by a
population of NO-producing cells that express CD11b and
CD33 and lack CD11c and HLA-DR, a phenotype suggestive
of MDSCs (Diaz-Montero et al., 2009; Gabrilovich and
Nagaraj, 2009). MDSCs are a heterogenous population of
myeloid cells that are enriched in the circulation of cancer
patients as well as in many animal tumor models. MDSCs
a iNOS iNOS iNOS/HLA-DR
iNOS/CD11biNOS/CD34iNOS/CD3iNOS/CD163
iNOS/CD11cb c d
e f g h
Figure 2. Inducible nitric oxide synthase–positive (iNOSþ ) cells infiltrating squamous cell carcinoma (SCC) tumors lack HLA-DR and express CD11b, a
phenotype consistent with myeloid-derived suppressor cells (MSDCs). (a, b) Costaining of SCC cryosections demonstrated that iNOSþ cells were evident in
SCC tumors. (c, d) iNOSþ cells lacked expression of the dendritic cell markers HLA-DR and CD11c, (e) the macrophage marker CD163, (f) the T-cell marker
CD3, and (g) the endothelial marker CD34. (h) iNOSþ cells did express the myeloid marker CD11b. CD11b expression together with a lack of HLA-DR
expression is a phenotype suggestive of MDSCs. Similar findings were observed in a total of eight SCC tumors. Scale bar¼ 100mM.
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play a major role in cancer-related immunosuppresssion and
can potently suppress T-cell responses (Nagaraj et al., 2010).
The majority of CD11bþCD11cHLA-DR cells isolated
from SCCs expressed iNOS, TGF-b, and arginase I, the three
critical effector mechanisms used by MDSCs to suppress
T-cell responses (Gabrilovich, 2004; Li et al., 2009; Jia et al.,
2010). CD11bþHLA-DR cells comprisedB6% of total cells
in SCCs, but were rare in normal skin (Figure 3c).
iNOS, a key enzyme that catalyzes NO production, is
expressed in a variety of human cancers including malignant
melanoma, breast, lung, prostate, and colorectal cancers
(Lechner et al., 2005). iNOS expression correlated with
progression in human astrocytoma and prostate cancer, and
patients with iNOSþ melanomas had decreased survival
(Lechner et al., 2005; Ekmekcioglu et al., 2006; Tanese et al.,
2011). NO has a variety of effects on immune cells including
inhibition of T-cell activation, proliferation, and cytokine
production (Bogdan, 2001), and animal studies suggest it may
also reduce the adhesion of leukocytes to blood vessels.
Inhibition of NO increased leukocyte rolling and adhesion in
mesenteric venules in cats and rats and P-selectin expression
was increased in rats after perfusion with NO inhibitors
(Kubes et al., 1991; Davenpeck et al., 1994). In a mouse
cancer model in which mouse mammary adenocarcinoma
and human colon carcinoma cell lines were injected into the
skin, treatment of animals with the iNOS inhibitor NG-nitro-
L-arginine methyl ester led to increased rolling and stable
adhesion of leukocytes to tumor vessels (Fukumura et al., 1997).
We find that NO is produced by SCC tumors and that
CD11bþ MDSCs expressed iNOS and are significant sources
of NO production within the SCC microenvironment. Small
numbers of CD11bþ HLA-DR/low cells isolated from SCCs
potently suppressed endothelial E-selectin expression, sug-
gesting that even though MDSCs comprise a relatively small
percentage of total tumor cells, they may play a critical role
in downregulating vascular E-selectin and impairing T-cell
trafficking into tumors. In a mouse model of B16 melanoma,
MDSCs inhibited the migration of activated CD8 T cells into
tumors but the mechanism of impaired T-cell homing was not
identified (Lesokhin et al., 2012). Our results suggest that NO
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Figure 3. Myeloid-derived suppressor cells (MDSCs) are a major source of nitric oxide (NO) production in squamous cell carcinoma (SCC) tumors. (a) SCC
tumors were dispersed by treatment with collagenase and the population of CD11bþHLA-DR cells was studied by flow cytometry. Most CD11bþHLA-DR
cells expressed CD33, approximately half expressed inducible nitric oxide synthase (iNOS), and over half produced transforming growth factor-b (TGF-b).
Representative histograms are shown and the mean and SEM of multiple donors are shown on the right (n¼5 for CD33 and iNOS, n¼ 3 for TGFb). (b) Arginase I
was increased in CD11bþ cells isolated by magnetic bead separation from collagenase-dispersed tumors as assayed by quantative real-time PCR. The mean and
SEM of three donors are shown. (c) In collagenase-dispersed tumors, a mean 6% of total tumor cells were CD11bþ HLA-DRCD33þ MDSCs but these cells
were rare in normal skin (Nml skin). (d) In many tumors, MDSCs represented the majority of iNOS-expressing cells but non-MDSC cell types also expressed
iNOS. (e) Analysis of SCC tumor supernatants using the Griess method demonstrated that NO was produced in SCC tumors. For each tumor, the mean and SEM
of duplicate measurements of nitrateþ nitrite are shown. (f, g) CD11bþ MDSCs from SCCs produce NO. CD11bþ MDSCs were enriched by magnetic bead
separation from collagenase-treated tumors and cultured in vitro. Culture supernatants were analyzed for the presence of NO by the Griess method. The mean
and SEM of measurements from three SCCs are shown.
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produced by MDSCs inhibits vascular E-selectin, likely
impairing T-cell migration in to tumors, and that this may
be another mechanism by which MDSCs impair antitumor
immunity.
Human studies have been limited but in vitro treatment of
HUVECs with NO has been shown to reduce addressin
expression and dendritic cell adhesion (De Caterina et al.,
1995; De Palma et al., 2006). We found that NO completely
abrogated the expression of E-selectin when DMECs were
physiologically stimulated with activated APCs, but could
only partially inhibit E-selectin expression when endothelial
cells were strongly and directly stimulated with 10 ngml1 of
TNF-a (Figure 4a and b). It may therefore be possible to
overcome impaired E-selectin expression by either inhibiting
iNOS activity or by potently and directly stimulating
endothelial cells. We found that HUVECs and DMECs
derived from human skin responded very similarly to NO,
suggesting that HUVECs, which are easier to obtain and
grow, may be useful in drug screens used to identify new
agents that activate endothelial cells.
MDSCs in both humans and animal models express the
chemokine receptor CCR2 (Huang et al., 2007; Lesokhin
et al., 2012). CCL2 is produced by human breast, gastric, and
ovarian cancers and inhibition of CCR2/CCL2 signaling in
mouse cancer models reduced MDSC migration and MDSC-
induced tumor cell growth (Huang et al., 2007). In addition to
their antimicrobial function, HBD2 and HBD3 can induce
cell chemotaxis via CCR2 (Rohrl et al., 2010). HBD3/CCR2
interactions promoted migration of macrophages into tumors
in a mouse model of oral carcinoma (Jin et al., 2010). We
found that iNOSþ MDSCs in SCC tumors expressed CCR2,
and SCC tumors expressed the CCR2 ligand HBD3, suggest-
ing that CCR2/HBD3 interactions may play a role in the
recruitment of MDSCs to tumors (Figure 5).
Last, we tested the ability of iNOS inhibitors and TNF-a to
restore E-selectin expression in freshly excised human SCC
tumors. iNOS inhibition alone markedly enhanced E-selectin
expression on tumor vessels (Figure 6). Remarkably, iNOS
inhibition alone induced E-selectin expression at similar
or greater levels than TNF-a. Moreover, E-selectin was
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in E-selectin expression was observed. Representative histograms and individual results from four SCC tumors are shown, along with the mean and SEM of
these measurements. (d, e) CD11bþ MDSCs from SCC tumors suppress endothelial E-selectin expression. CD11bþ and CD11b cell populations were obtained
by magnetic bead separation from collagenase-dispersed SCC tumors. HUVECs were stimulated with TNF-a in the presence or absence of CD11bþ and
CD11b cells. (d) Representative histograms and (e) individual results from three SCC tumors are shown, along with the mean and SEM of these measurements.
CD11bþ MDSCs reproducibly inhibited expression of endothelial E-selectin. APC, antigen presenting cell.
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expressed at levels comparable to those observed in SCCs
undergoing immunologic destruction after topical treatment
with TLR7 agonist (Figures 1d and 6b). SCCs undergoing
immunologic destruction after TLR7 agonist therapy ex-
pressed E-selectin on a mean 34.2% of blood vessels as
compared with 27.2% of blood vessels following in vitro
treatment with iNOS inhibitor (P40.05). Although the
limitations of working with humans preclude us from directly
demonstrating that T-cell recruitment into SCCs is enhanced
as a result of iNOS inhibition, these studies strongly suggest
that iNOS inhibition induces vascular E-selectin at levels
capable of enhancing T-cell entry into tumors. To our
knowledge, it is previously unreported in a human cancer
that iNOS activity impairs the expression of vascular
addressins critical for T-cell recruitment.
Our results suggest that treatment with iNOS inhibitors or
potent stimulators of endothelial activation both have the
potential to restore addressin expression in SCCs without the
attendant widespread immune activation observed with TLR
agonists such as imiquimod. A topically applied inhibitor of
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Figure 5. Myeloid-derived suppressor cells (MDSCs) from squamous cell carcinomas (SCCs) express CCR2 (chemokine (C-C motif) receptor 2) and SCCs
produce the CCR2 ligand human b-defensin 3 (HBD3). (a) CD11bþHLA-DR MDSCs from collagenase-dispersed SCCs uniformly expressed CCR2, whereas
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ligand HBD3 in SCCs. (d) Immunostaining of SCC cryosections confirmed production of HBD3 by SCC tumor cells. Scale bar¼ 100mM.
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iNOS is currently in clinical trials for the treatment of
neuropathic pain (LaBuda et al., 2006). Because immune
evasion in SCCs is primarily an issue of impaired T-cell
homing, our studies suggest that topically applied iNOS
inhibitors or potent endothelial activating agents may be
effective, either alone or in combination with other therapies,
in the treatment of SCCs and their premalignant precursor
lesions, actinic keratoses.
It is becoming increasingly appreciated that cancer destruc-
tion requires not only the generation of tumor-specific T cells,
but also the ability of these T cells to access the tumor once
they are generated (Gajewski, 2007). Impaired T-cell homing
as a result of decreased vascular addressin expression has been
reported in a number of human cancers, including malignant
melanoma, breast, gastric, and lung cancers (Piali et al., 1995;
Madhavan et al., 2002; Weishaupt et al., 2007). Melanoma
metastases express low levels of the addressins E-selectin,
P-selectin, and ICAM-1, and this is associated with low
numbers of T cells within the metastatic tumor nodules
(Weishaupt et al., 2007). Our work suggests that local
production of NO within tumors could be a common
mechanism for impaired T-cell homing. If this proves to be
the case, iNOS inhibition used in concert with agents that
enhance the presentation of tumor antigens have the potential
to enhance immune responses to many human cancers.
MATERIALS AND METHODS
SCC samples
Tumor samples consisted of tumors removed before taking the first
Moh’s section during Moh’s micrographic excision of biopsy-proven
squamous cell carcinomas removed from immunocompetent in-
dividuals. Acquisition of tumor samples and all studies were
approved by the Partners Institutional Review Board and were
performed in accordance with the Declaration of Helsinki Princi-
ples. Because this work utilized discarded tissues with no identifi-
able personal information, the partners IRB ruled that no informed
written patient consent was required.
Immunofluorescence studies
Sections (5mm) were cut from SCC blocks frozen in optimal cutting
temperature compound. They were fixed in acetone, air dried, rehy-
drated in phosphate-buffered saline, and blocked with human IgG
(Jackson Immunoresearch, West Grove, PA). Sections were incubated
with a biotinylated anti-E-selectin (clone 68-5H11, BD) at 5mgml1,
rinsed in phosphate-buffered saline/1% BSA, and costained with
streptavidin/phycoerythrin (1mgml1, R&D Systems, Minneapolis,
MN) and CD31 FITC (1:40 clone WM59, BD, Franklin Lakes, NJ).
Sections were rinsed and mounted with ProLong Gold antifade reagent
with 4,6-diamidino-2-phenylindole (Invitrogen, Grand Island, NY).
E-selectinþ blood vessels were enumerated in ten  100 HPFs. To
quantify CLAþ T cells, sections were costained with phycoerythrin
anti-CD3 (1:40, BD) and FITC anti-CLA (1:25, BD). The number of
CLAþ infiltrating T cells was determined by counting CLAþ cells
directly in 10 HPFs or by counting total T cells in 10 HPFs and
multiplying by the % CLAþ T cells of total T cells obtained from 5
HPFs. For examination of iNOS-expressing cells, sections were
costained with directly conjugated mAbs (BD) and FITC anti-iNOS
(1:20, BD). For HBD3 staining, sections were stained with rabbit anti
human HBD3 mAb (1:00, FL-67 Santa Cruz Biotech, Santa Cruz, CA)
followed by Alexa Fluor 488 goat anti rabbit polyclonal antibody
(1:100, Invitrogen). In all studies, 4,6-diamidino-2-phenylindole
nuclear stain was used to confirm the presence of invasive tumor
as determined by the presence of large atypical keratinocyte nuclei.
Sections were photographed using a Nikon Eclipse 6600 microscope
equipped with Nikon Plan Fluor objective lenses, Nikon (Melville,
NY). Images were captured with a SPOT RT model 2.3.1 camera
(Diagnostic Instruments, Sterling Heights, MI) and were acquired
with SPOT 4.0.9 software (Diagnostic Instruments).
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Figure 6. Inhibition of inducible nitric oxide synthase (iNOS) activity restores vascular E-selectin expression in squamous cell carcinoma (SCC) tumors.
(a) In vitro treatment of human SCCs induced vascular E-selectin expression. SCC tumors were cultured for 24 hours in medium alone, tumor necrosis factor-a
(TNF-a), or with the iNOS inhibitor No-nitro-L-arginine (L-NNA). Tumors were then cryosectioned and stained for vascular E-selectin expression. SCCs treated
with TNF-a or iNOS inhibitor showed induction of vascular E-selectin expression on a subset of vessels. (b) iNOS inhibition potently induced vascular E-selectin
expression. The mean and SEM of the % E-selectin expressing vessels in 10 high-power fields are shown. In vitro treatment of tumors with iNOS inhibitor
induced vascular E-selectin at levels comparable to or greater than that observed after treatment with TNF-a. Results from four SCC tumors are shown;
comparable results were observed in seven additional SCCs. NS, not significant. *Po0.05, **Po0.01, ***Po0.0005. Scale bar¼ 500mM.
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Isolation and flow cytometry analysis of T cells and MDSCs
from SCC tumors
For isolation of MDSCs from SCCs, tumors were minced and
dissociated with 0.2% type I collagenase (Invitrogen) and 30Kunitz
Unitsml1 of DNAse (Sigma, St Louis, MO) for 2 hours at 37 1C with
vigorous shaking. CD11bþ cells were isolated from collagenase-
treated tumors by staining with anti-CD11b-phycoerythrin mAb
(R&D systems) and anti-phycoerythrin micro-beads (Miltenyi Bio-
tech, Auburn, CA) followed by AutoMACS separation (Miltenyi
Biotech). For TGF-b staining, cells were stimulated overnight with
1mgml1 lipopolysaccharide from E. coli (Sigma) and 100 IUml1
IFN-g (R&D systems) to activate MDSCs (Greifenberg et al., 2009).
Flow cytometry analysis was performed using directly conjugated
mAbs from BD. Analysis of flow cytometry samples was performed
on a Becton Dickinson FACSCanto instrument and data were
analyzed using FACSDiva software (BD).
Assay of SCC supernatants and CD11bþ cells for NO
production
For analysis of SCC supernatants, 3mm3 tumor fragments were
cultured for 24 hours in Iscoves medium supplemented with 10%
human AB serum, fungizone, gentamicin, penicillin/streptomycin,
L-glutamine and 0.6mM L-arginine. Supernatants were concentrated
using Microcon centrifugal filter devices (Millipore, Billerica, MA).
For analysis of NO production from SCC CD11bþ cells, CD11bþ
cells were isolated from collagenase-treated SCCs by magnetic bead
separation as described and 10,000 CD11bþ cells were incubated
for 12 hours with 1mgml1 E. coli lipopolysaccharide and
100 IUml1 IFN-g. Supernatants were assayed for NO using the
QuantiChrom Nitric Oxide assay kit or the Parameter Total NO/
Nitrite/Nitrate Assay Kit (R&D Systems), as per the manufacturer’s
instructions.
Endothelial cell studies
Human DMECs and HUVECs (Lonza, Walkersville, MD) were cultured
in EGM-2 bulletkit growth medium (Lonza). Endothelial cells at 90%
confluency were stimulated for 12hours with activated APCs or
10ngml1 TNF-a (R&D systems) with or without 0.5mM NO donor
spermine NONOate (Sigma). Human peripheral blood APCs were
isolated from products discarded following plasmapheresis of healthy
donors by density centrifugation using histopaque-1077 (Sigma) and
depletion of T cells using the Pan-T isolation kit and AutoMACS
instrument (Miltenyi Biotech). APCs (2.5 106) and 3mM imiquimod
(added to stimulate APCs) were added to wells containing cultured
endothelial cells for 12hours. Endothelial cells were then stained with
directly conjugated antibodies to CD31 and E-selectin (BD) and
acquired on a BD FACSCanto flow cytometer. Data were analyzed
using FACSDiva software (V6.1). For experiments involving cocultures
of endothelial cells with cells from SCC tumors, cells obtained from
collagenase-treated SCCs were rested overnight at in complete Iscove’s
medium in the presence of 10ngml1 GM-CSF (R&D systems) to
maintain myeloid cell viability (Ko et al., 2009). Cells from SCCs were
added to endothelial cells in a 1:1 ratio and stimulated with 1ngml1
TNF-a (R&D systems). In a second group of experiments, 5,000
AutoMACS-enriched CD11bþ cells from collagenase-treated SCCs
were added to wells containing 5,000 endothelial cells stimulated with
TNF-a 1ngml1; immunostaining of endothelial cells was performed
12hours later as described.
Quantitative real-time PCR for CCR2 ligands and arginase I
Total RNA was isolated from cryosections of SCCs and normal skin
or from cells isolated from SCC tumors using the RNeasy Lipid Tissue
kit (Qiagen, Valencia, CA), according to the manufacturer’s
instructions. Complementary DNA was generated using the Quanti-
Tect reverse transcription kit (Qiagen) and quantitative real-time PCR
was performed using the ABI StepONE plus instrument and the Fast
SYBR green master mix (Applied Biosystems, Carlsbad, CA).
Expression of each ligand transcript was determined relative to the
reference gene transcript, glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH), and calculated as 2^(Ct, ligandCt, GAPDH). The
primers used to detect the ligands and the reference transcripts were
purchased from Origene Technologies (Rockville, MD) and were as
follows: hBD2 (F-50-GGCGTAGAAGTTCTCTGTCTCC-30; R-50-
GAAGCAGGAGAAAAGGATGGAG-30), hBD3 (F-50-GGTGAAG
CCTAGCAGCTATGAG-30; R-50-GCCGCCTCTGACTCTGCAATA-30),
CCL2 (F-50-AGAATCACCAGCAGCAAGTGTCC-30, R-50-TCCTGAA
CCCACTTCTGCTTGG-30), CCL7 (F-50-ACAGAAGGACCACCAGTAG
CCA-30; R-50-GGTGCTTCATAAAGTCCTGGACC-30), CCL13 (F-50-GA
TCTCCTTGCAGAGGCTGAAG-30; R-50-TCTGGACCCACTTCTCCTTT
GG-30), and GAPDH (F-50-GAGTCAACGGATTTGGTCGT-30; R-50-CAT
GGGTGGAATCATATTGGA-30).
In vitro treatment of SCCs with iNOS inhibitor and TNF-a
SCCs were cultured for 24 hours in control medium (Iscoves, 10%
human AB serum, fungizone, gentamicin, penicillin/streptomycin,
L-glutamine, 0.6mM L-arginine) in the presence or absence of 0.6mM
iNOS inhibitor L-NNA (Sigma) and/or 10 ngml1 TNF-a (R&D), then
embedded in optimal cutting temperature compound, cryosectioned
and stained for CD31 and E-selectin as described.
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